FDA publishes ICH Q4B - Annex 13 on Density of Powders
Recommendation

6/7 October 2026
Dealing with different compendial methods
On 28 May 2013, the FDA also finally published the ICH harmonised Guideline entitled "Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Bulk Density and Tapped Density of Powders - General Chapter (Q4B Annex 13)".
This ICH Guideline thus came into force in the USA, too.
The objective of the ICH Q4B Working Group is to reach mutual recognition by regulatory authorities in the ICH regions for all testing methods listed in the ICH Q6A Guideline on Specifications.
Through this, comparable testing laid down in the different pharmacopoeias shouldn't be performed separately when it has been assessed by authorities that those are similar and interchangeable.
Nevertheless, the FDA might request - if necessary - that a company demonstrates that the chosen method is acceptable and suitable for a specific material or product, irrespective of the origin of the method. This "Disclaimer" can be found in all the ICH Q4B Annexes. No one knows whether the FDA has already posed such questions.
For details please see the FDA Q4B - Annex 13.
Related GMP News
16.09.2026USP-NF Publishes Responses to Comments on Stimuli Article on Apex Vessel Geometries
03.09.2026USP Article: Supporting the Detection of Asbestos in Pharmaceutical Talc
03.09.2026Analytical Quality Group Developments May through August 2026
02.09.2026USP Publishes Comments Received on Chapter <320>
26.08.2026New USP Requirements for Asbestos Testing in Pharmaceutical Talc


